Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 5, 2005 - Issue 5
Submit an article Journal homepage
47
Views
4
CrossRef citations to date
0
Altmetric
Review

Immunotherapy and immunoprevention of cancer: where do we stand?

Federica CavalloUniversity of Turin Department of Clinical and Biological Sciences, Ospedale San Luigi Gonzaga, I-10043 OrbassanoItalyTel: +39 011 670 5419; Fax: +39 011 236 5417;E-mail: [email protected]
,
Claudia Curcio E-mail: [email protected]
&
Guido Forni E-mail: [email protected]
Pages 717-726 | Published online: 24 Nov 2005

Bibliography

  • MITCHISON NA: The immunogenicity of tumors. In: Cytokine-Induced Tumor Immunogeniciiy. From Exogenous Molecules to Gene Therapy. Forni G, Foa R, Santoni A, Frati L (Ed.), Academic Press Limited, London, UK (1994):3–11.
  • ••A critical evaluation oftumour immunotherapy.
  • ERLICH P: Uber den jetzigen stand der karzinomforschung. Ned. lijdschr. Geneeeskd. (1909) 5:273–290.
  • ROSENBERG SA, YANG JC, RESTIFO NP: Cancer immunotherapy: moving beyond current vaccines. Nat. Med. (2004) 10(9):909–915.
  • •A meditation on the poor outcome of therapeutic vaccination.
  • PARMIANI G, PILLA L, CASTELLI C, RIVOLTINI L: Vaccination of patients with solid tumours. Ann. Oncol (2003) 14(6):817–824.
  • •An authoritative review of the results obtained.
  • HERICOURT J, RICHET C: Traitment d'un cas de sarcome par la serotherapie. Compte rendu hebdomadaire des sceances de PAcadamie des sciences (1895) 120(7):948–952.
  • HOUGHTON AN, LLOYD KO: Stuck in the MUC on the long and winding road. Nat. Med. (1998) 4(3):270–271.
  • ••A witty comment on the T cell chauvinismtaking over tumour immunology.
  • SJOGREN HO, HELLSTROM I, BANSAL SC, HELLSTROM KE: Suggestive evidence that the 'blocking antibodies' of tumor-bearing individuals may be antigen-antibody complexes. Proc. Natl Acad. Sci. USA (1971) 68(6):1372–1375.
  • •A suggestive way to put immunotherapy into a historical perspective.
  • KOHLER G, MILSTEIN C: Continuous cultures of fused cells producing antibodies of predefined specificity. Nature (1981) 256:495–497.
  • ••A landmark paper.
  • VON MEHREN M, ADAMS GP, WEINER LM: Monoclonal antibody therapy for cancer. Annu. Rev. Med. (2003) 54:343–369.
  • •A detailed reference review.
  • DENNY WA: Tumor-activated prodrugs-a new approach to cancer therapy. Cancer Invest. (2004) 22(4):604–619.
  • ROSENBLUM M: Immunotoxins and toxin constructs in the treatment of leukemia and lymphoma. Adv. Pharmacol (2004) 51:209–228.
  • •A thorough review of immunotoxins.
  • YOSHIOKA Y, TSUTSUMI Y, NAKAGAWA S, MAYUMI T: Recent progress on tumor missile therapy and tumor vascular targeting therapy as a new approach. Curr. Vasc. Pharmacol (2004) 2(3):259–270.
  • DYBA M, TARASOVA NI, MICHEJDA CJ: Small molecule toxins targeting tumor receptors. Curr. Pharm. Des. (2004) 10(19):2311–2334.
  • RIETHMULLER G, SCHNEIDER-GADICKE E, SCHLIMOK G et al.: Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group. Lancet (1994) 343(8907):1177–1183.
  • RIETHMULLER G, HOLZ E, SCHLIMOK Get al.: Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J. Clin. Oncol. (1998) 16(5):1788–1794.
  • ••A landmark paper on the use of mAbs intumour prevention.
  • ROQUE AC, LOWE CR, TAIPA MA: Antibodies and genetically engineered related molecules: production and purification. BiotechnoL Prog. (2004) 20(3):639–654.
  • MALONEY D, GRILLO-LOPEZ A, BODKIN D et al.: IDEC-C2B8: results of a Phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J. Clin. Oncol. (1997) 15:3266–3274.
  • MALONEY D, GRILLO-LOPEZ A, WHITE C: IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood (1997) 90:2188–2195.
  • COBLEIGH M, VOGEL C, TRIPATHY D et al.: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. (1999) 17:2639–2648.
  • BASELGA J, TRIPATHY D, MENDELSOHN J et al.: Phase II study of weekly intravenous recombinant humanized antip185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol. (1996) 14:737–744.
  • SATO JD, KAWAMOTO T, LE AD, MENDELSOHN J, POLIKOFF J, SATO GH: Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. MoL Biol. Med. (1983) 1(5):511–529.
  • BASELGA J, PFISTER D, COOPER MR et aL: Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. j Clin. Oncol. (2000) 18:904–914.
  • SALTZ LB, MEROPOL NJ, LOEHRER PJ SR, NEEDLE MN, KOPIT J, MAYER RJ: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor./ Clin. Oncol. (2004) 22(7):1201–1208.
  • HINODA Y, SASAKI S, ISHIDA T, IMAI K: Monoclonal antibodies as effective therapeutic agents for solid tumors. Cancer Sci. (2004) 95(8):621–625.
  • •A thorough review of mAbs against solid tumours.
  • HALE G, ZHANG M, BUNJES D et aL:Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood (1998) 92:4581–4590.
  • BOWEN A, ZOMAS A, EMMETT E et aL: Subcutaneous CAMPATH-1H in fludarabine-resistandrelapsed chronic lymphocytic and B-prolymphocytic leukaemia. Br. J. HaematoL (1997) 96:617–619.
  • LUNDIN J, OSTERBORG A, BRITTINGER G et aL: CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a Phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. J. Clin. Oncol. (1998) 16:3257–3263.
  • GORDON M, MARGOLIN K, TALPAZ M et aL: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. Clin. Oncol. (2001) 19:843–850.
  • FERRARA N: Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. (2004) 25(4):581–611.
  • •An inspiring review of the potential of antiangiogenic therapy.
  • PRICE N: Bevacizumab improves the efficacy of 5-fluorouracil/leucovorin in patients with advanced colorectal cancer. Clin. Colorectal Cancer (2004) 4(2):89–91.
  • GRAHAM J, MUHSIN M, KIRKPATRICK P: Bevacizumab. Nat. Rev. Drug Discov. (2004) 3(12):995–996.
  • CRAWFORD LM JR: From the Food and Drug Administration. JAMA (2002) 287(13):1640.
  • THEUER CP, LEIGH BR, MULTANI PS, ALLEN RS, LIANG BC: Radioimmunotherapy of non-Hodgkin's lymphoma: Clinical development of the Zevalin regimen. BiotechnoL Annu. Rev. (2004) 10:265–295.
  • ZELENETZ AD: A clinical and scientific overview of tositumomab and iodine 1131 tositumomab. Semin. Oncol. (2003) 30(2 Suppl. 4):22–30.
  • HORNING SJ, YOUNES A. JAIN Vet aL: Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. Clin. Oncol. (2005) 23(4):712–719.
  • VOSE JM: Bexxar: novel radioimmunotherapy for the treatment of low-grade and transformed low-grade non-Hodgkin's lymphoma. Oncologist (2004) 9(2):160–172.
  • GILES FJ: Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia. Expert Rev. Anticancer Ther. (2002) 2(0:630–640.
  • ROSS JS, SCHENKEIN DP, PIETRUSKO R et al.: Targeted therapies for cancer 2004. Am. J. Clin. Pathol. (2004) 122(4):598–609.
  • MILOWSKY MI, NANUS DM, KOSTAKOGLU L, VALLABHAJOSULA S, GOLDSMITH SJ, BANDER NH: Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer./ Clin. Oncol. (2004) 22(13):2522–2531.
  • KREITMAN RJ, WILSON WH, BERGERON K et al.: Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl. J. Med. (2001) 345(4):241–247.
  • BARTH S: Technology evaluation: BL22, NCI. Curr. Opin. Mob. Ther. (2002) 4(1):72–75.
  • KREITMAN RJ: Recombinant immunotoxins for the treatment of haematological malignancies. Expert. Opin. Biol. Ther. (2004) 4(7):1115–1128.
  • •A comprehensive review of the potential of immunotoxins in cancer therapy.
  • JERNE NK: Towards a network theory of the immune system. Ann. ImmunoL (Paris) (1974) 125:373–389.
  • TSUJISAKI M, IMAI K, TOKUCHI S et al.: Induction of antigen-specific immune response with use of antiidiotypic monoclonal antibodies to anti-carcinoembryonic antigen antibodies. Cancer Res. (1991) 51:2599–2604.
  • HINODA Y, SASAKI S, ISHIDA T, IMAI K: Monoclonal antibodies as effective therapeutic agents for solid tumors. Cancer Sci. (2004) 95(8):621–625.
  • ROQUE AC, LOWE CR, TAIPA MA: Antibodies and genetically engineered related molecules: production and purification. BiotechnoL Prog (2004) 20(3):639–654.
  • •A thorough review of the possibilities of genetically engineering an antibody molecule.
  • KATAOKA A, ISHIDA M, MURAKAMI S, OHNO S: Sensitization of chemotherapy by anti-HER. Breast Cancer (2004) 11:105–115.
  • WHITWORTH PW, PAK CC, ESGRO J, KLEINERMAN ES, FIDLER IJ: Macrophages and cancer. Cancer Metastasis Rev. (1990) 8(4):319–351.
  • •A historical paper on the activation of macrophages as anticancer cells.
  • ROSENBERG SA, LOTZE MT, MUUL LM et al.: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl. J. Med. (1987) 316(15):889–897.
  • ••A landmark paper on adoptive therapy.
  • ROSENBERG SA, LOTZE MT, MUUL LM et al.: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl. J. Med. (1985) 313(23):1485–1492.
  • ••A landmark paper on adoptive therapy.
  • DUDLEY ME, WUNDERLICH JR, ROBBINS PF et al.: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. (2002) 298(5594):850–854.
  • DUDLEY ME, ROSENBERG SA: Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat. Rev. Cancer (2003) 3(9):666–675.
  • BLATTMAN JN, GREENBERG PD: Cancer immunotherapy: a treatment for the masses. Science (2004) 305(5681):200–205.
  • ••A manifesto on the potential of adoptiveT cell therapy in cancer.
  • GUSTAFSSON A, LEVITSKY V, ZOU JZ et al.: Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood (2000) 95(3):807–814.
  • COMOLI P, LABIRIO M, BASSO S et al: Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood (2002) 99(7):2592–2598.
  • BOLLARD CM, AGUILAR L, STRAATHOF KC et al.: Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J. Exp. Med. (2004) 200(12):1623–1633.
  • GOTTSCHALK S, HESLOP HE, ROONEY CM: Adoptive immunotherapy for EBV-associated malignancies. Leuk. Lymphoma (2005) 46(1):1–10.
  • COOLEY WB: The treatment of malignant tumors by repeated inoculations of erysipelas; with a report of ten original cases. Am. J. Med. Sci. (1893) 105(3):183–212.
  • ••A landmark historical paper.
  • OLD LJ: Tumor immunology: the first century. Curr. Opin. Immunol (1992) 4(5):603–607.
  • ••A moving historical perspective.
  • TAKEDA K, AKIRA S: TLR signaling pathways. Semin. Immunol. (2004) 16(1):3–9.
  • ZBAR B, HUNTER JT, RAPP HJ, CANTI GF: Immunotherapy of bilateral lymph node metastases in guinea pigs by intralesional or paralesional injection of Mycobacterium bovis (BCG). j Natl Cancer Inst. (1978) 60(5):1163–1168.
  • GRUNHAGEN DJ, BRUNSTEIN F, TEN HAGEN TL, VAN GEEL AN, DE WILT JH, EGGERMONT AM: TNF-based isolated limb perfusion: a decade of experience with antivascular therapy in the management of locally advanced extremity soft tissue sarcomas. Cancer Treat. Res. (2004) 120:65–79.
  • ••A report on the astonishing potential oflocal TNF.
  • MOLIFE R, HANCOCK BW: Adjuvant therapy of malignant melanoma. Crit. Rev. Oncol HematoL (2002) 44 (1) :81–102.
  • MORALES A, EIDINGER D, BRUCE AW: Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J. Urol (1976) 116:180–183.
  • LAMM DL: Bacillus Calmette-Guerin immunotherapy for bladder cancer. J. Urol (1985) 134:40–47.
  • HERR H: Current results, natural history and implications for urothelial cancer prevention. J. Cell Biol. (1992) 161(Suppl.):12–19.
  • SHELLEY MD, WILT TJ, COURT J, COLES B, KYNASTON H, MASON MD: Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int. (2004) 93(4):485–490.
  • KRIEG AM: CpG motifs: the active ingredient in bacterial extracts? Nat. Med. (2003) 9:831–835.
  • NAGATA S, TAIRA H, HALL A et al: Synthesis in E. coli of a polypeptide with human leukocyte interferon activity. Nature (1980) 284:316–320.
  • HUBER CH, WOLFEL T: Immunotherapy of cancer: from vision to standard clinical practice. J. Cancer Res. Clin. Oncol (2004) 130:367–374.
  • AULITZKY WE, HUBER C, PESCHEL C: Cytokine therapy of neoplastic and inflammatory disease. Int. Arch. Allergy Immunol (1993) 101:221–226.
  • ATKINS MB, REGAN M, MCDERMOTT D: Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin. Cancer Res. (2004) 10(18 Pt 2):63425–63465.
  • FANELLI MC, WHITE R, FOSTER M et al.: Forecasting the cytokine storm following systemic interleukin (IL)-2 administration. J. Transl Med. (2004) 2(1):17.
  • MUSIANI P, MODESTI A, GIOVARELLI M et al.: Cytokines, tumour-cell death and immunogenicity: a question of choice. Immunol lbday (1997) 18(1):32–36.
  • ••A manifesto on the use of local cytokines.
  • CORTESINA G, DE STEFANI A, GALEAZZI E et al.: Interleukin-2 injected around tumor-draining lymph nodes in head and neck cancer. Head Neck (1991) 13(2):125–131.
  • DE STEFANI A, FORNI G, RAGONA R et al.: Improved survival with perilymphatic interleukin 2 in patients with resectable squamous cell carcinoma of the oral cavity and oropharynx. Cancer (2002) 95W:90–97.
  • ROSENBERG SA: Progress in human tumor immunology and immunotherapy. Nature (2001) 411:380–383.
  • •A positive balance of the achievements of cell-mediated immunotherapy in cancer.
  • LOLLINI PL, FORNI G: Antitumor vaccines: is it possible to prevent a tumor? Cancer Immunol Immunother. (2002) 51:409–416.
  • •A review suggesting new perspectives in the use of tumour vaccines.
  • RIBAS A, BUTTERFIELD LH, GLASPY JA, ECONOMOU JS: Current developments in cancer vaccines and cellular immunotherapy. j Clin. Oncol (2003) 21(12):2415–2432.
  • MOCELLIN S, MANDRUZZATO S, BRONTE V, MARINCOLA FM: Correspondence 1: Cancer vaccines: pessimism in check. Nat. Med. (2004) 10(12):1278–1279.
  • FINN OJ: Cancer vaccines: between the idea and the reality. Nat. Rev. Immunol (2003) 3(8):630–641.
  • CAMPOLI M, FERRONE S: T-cell-based immunotherapy of melanoma: what have we learned and how can we improve? Expert Rev. Vaccines (2004) 3(2):171–187.
  • •A critical balance of the achievements of cell-mediated immunotherapy in cancer.
  • DUNN GP, OLD LJ, SCHREIBER RD: The immunobiology of cancer immunosurveillance and immunoediting. Immunity (2004) 21(2):137–148.
  • •A paper drawing a new form of old concepts.
  • BOCCHIA M, BRONTE V, COLOMBO MP et al.: Antitumor vaccination: where we stand. Haematologica (2000) 85(11):1172–1206.
  • ••A systematic review of vaccine strategies incuring cancer.
  • COULIE PG, IKEDA H, BAURAIN JF, CHIARI R: Antitumor immunity at work in a melanoma patient. Adv. Cancer Res. (1999) 76:213–242.
  • MELANI C, CHIODONI C, FORNI G, COLOMBO MP: Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood (2003) 102(6):2138–2145.
  • SAKAGUCHI S: Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. (2004) 22:531–562.
  • PISA P, HALAPI E, PISA EK et al: Selective expression of interleukin 10, interferon gamma, and granulocyte-macrophage colony-stimulating factor in ovarian cancer biopsies. Proc. Natl Acad. Sci. USA (1992) 89(16):7708–7712.
  • GABRILOVICH DI, CHEN HL, GIRGIS KR et al: Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. (1996) 2(10):1096–1103.
  • TAHERI F, OCHOA JB, FAGHIRI Z et al: L-Arginine regulates the expression of the T-cell receptor zeta chain (CD3zeta) in Jurkat cells. Clin. Cancer Res. (2001) 7(3 Suppl.):958s–965s.
  • HAHNE M, RIMOLDI D, SCHROTER M et al: Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science (1996) 274(5291):1363–1366.
  • GIOVARELLI M, MUSIANI P, GAROTTA G et al: A 'stealth effect': adenocarcinoma cells engineered to express TRAIL elude tumor-specific and allogeneic T cell reactions. J. Immunol (1999) 163(9):4886–4893.
  • FINN OJ: Premalignant lesions as targets for cancer vaccines. J. Exp. Med. (2003) 198(11):1623–1626.
  • •A suggestive paper on the importance of finding new antigens expressed by premalignant lesions.
  • FORNI G, LOLLINI PL, MUSIANI P, COLOMBO MP: Immunoprevention of cancer: is the time ripe? Cancer Res. (2000) 60:2571–2575.
  • ••A cancer immunoprevention manifesto.
  • FINN OJ, FORNI G: Prophylactic cancer vaccines. Cuff. Opin. Immunol (2002) 14(2):172–177.
  • •A review of the potential of vaccines to prevent cancer.
  • CRAGG MS, MORGAN SM, CHAN HT et al: Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood (2003) 101(3):1045–1052.

Websites

  • http://www.clinicaltrials.gov ClinicalTrials.gov Information on Clinical Trials and Human Research Studies. Search results for cancer [ALL-FIELDS] AND immunotherapy [ALL-FIELDS] gave 759 studies.
  • http://www.eortc.be/protoc/listtrt.asp EORT European Organization for Research and Treatment of Cancer. Search of protocols by treatment gave 6 protocols using interferon, 31 protocols of immunotherapy, and 27 protocols using biological response modifiers).
  • http://www.cancer.org/docroot/ETO/ content/ ET0_1_4X_Monoclonal_Antibody_Therap y_Passive_Immunotherapy.asp?sitearea=ETO American Cancer Society, Monoclonal Antibody Therapy (Passive Immunotherapy).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.